Lilly Claims Proof Of Concept For Neutralizing Antibodies In COVID-19 Therapy
Analysts called the interim data from a Phase II study of LY-CoV555 mixed, but Lilly insists that it has demonstrated a therapeutic role for neutralizing antibodies in fighting the novel coronavirus.
You may also be interested in...
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.
Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial.